RNA with Azvudine incorporated one nucleotide upstream of 3’-end resists cleavage by SARS-CoV-2 proofreading exonuclease
Abstract
The cytidine analog Azvudine (Azv) showed promising therapeutic effects against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections, leading to its conditional authorization as a COVID-19 treatment in China. Once Azvudine enters infected cells, it is converted to the active form, Azvudine-triphosphate, which has been shown to inhibit polymerases of several viruses. Here we show that when Azvudine is incorporated into RNA by the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), it hinders incorporation of the subsequent nucleotide, but this hindrance can be partially overcome in the presence of natural nucleotides. Moreover, the 3’-Azv-terminated RNA does not show any resistance to the SARS-CoV-2 proofreading exonuclease (ExoN). However, we found that the incorporation of Azvudine at the penultimate position of the RNA prevents RNA cleavage by the ExoN. Because Azvudine partially terminates RNA synthesis and 3’-Azv-terminated RNA does not show any ExoN resistance, the penultimate ExoN-resistant RNA configuration is a less frequent event. Although these finding do not establish a direct RdRp-mediated inhibition as the primary reason for reported Azvudine’s therapeutic effect, the position-dependent ExoN resistance observed here provide mechanistic insight for the development of novel nucleotide analogs that potentially inhibit RdRp and resist the viral proofreading mechanism of coronaviruses.
Related
- Exonuclease 1 drives immune escape in lung adenocarcinoma by regulating the HIF-1α/PD-L1 axis
- Identification and prognostic value of non-hotspot POLE exonuclease domain mutations in endometrial cancer
- Cancer-derived lactic acid as a potential upstream contributor to tumor hypoxia
- When Mammary-Like Anogenital Glands Go Rogue: Vulvar Phyllodes Tumor With Incorporated Hidradenoma Papilliferum.
- Optimization of Hydrophobic Group Structures Covalently Incorporated into Gelatin Hydrogels for Efficient Adsorption and Release of Hydrophobic Drugs.
BibTeX
@article{yue2026with,
title = {{RNA with Azvudine incorporated one nucleotide upstream of 3’-end resists cleavage by SARS-CoV-2 proofreading exonuclease}},
author = {Ying Tong Yue and Kao Lin and Chuanjuan Tao and Xiaoxu Li and Shuxia Peng and Marianna Teplova and Shiv Kumar and Irina Morozova and Sergey Kalachikov and James J. Russo and Dinshaw J. Patel and Jingyue Ju},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-73194-3},
url = {https://www.nature.com/articles/s41598-026-73194-3},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - RNA with Azvudine incorporated one nucleotide upstream of 3’-end resists cleavage by SARS-CoV-2 proofreading exonuclease
AU - Ying Tong Yue
AU - Kao Lin
AU - Chuanjuan Tao
AU - Xiaoxu Li
AU - Shuxia Peng
AU - Marianna Teplova
AU - Shiv Kumar
AU - Irina Morozova
AU - Sergey Kalachikov
AU - James J. Russo
AU - Dinshaw J. Patel
AU - Jingyue Ju
PY - 2026
DA - 2026/10/04
JO - Scientific Reports
DO - 10.1038/s41598-026-73194-3
UR - https://www.nature.com/articles/s41598-026-73194-3
AB - The cytidine analog Azvudine (Azv) showed promising therapeutic effects against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections, leading to its conditional authorization as a COVID-19 treatment in China. Once Azvudine enters infected cells, it is converted to the active form, Azvudine-triphosphate, which has been shown to inhibit polymerases of several viruses. Here we show that when Azvudine is incorporated into RNA by the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), it hinders incorporation of the subsequent nucleotide, but this hindrance can be partially overcome in the presence of natural nucleotides. Moreover, the 3’-Azv-terminated RNA does not show any resistance to the SARS-CoV-2 proofreading exonuclease (ExoN). However, we found that the incorporation of Azvudine at the penultimate position of the RNA prevents RNA cleavage by the ExoN. Because Azvudine partially terminates RNA synthesis and 3’-Azv-terminated RNA does not show any ExoN resistance, the penultimate ExoN-resistant RNA configuration is a less frequent event. Although these finding do not establish a direct RdRp-mediated inhibition as the primary reason for reported Azvudine’s therapeutic effect, the position-dependent ExoN resistance observed here provide mechanistic insight for the development of novel nucleotide analogs that potentially inhibit RdRp and resist the viral proofreading mechanism of coronaviruses.
SN - 2045-2322
ER -